Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology

Hum Reprod. 2006 Jan;21(1):159-63. doi: 10.1093/humrep/dei270. Epub 2005 Aug 25.

Abstract

Background: Pre-antral and early antral follicles secrete Müllerian inhibiting substance (MIS), suggesting that MIS may directly reflect ovarian reserve. Since little is known about how ovarian reserve affects oocyte quality, we attempt here to assess the predictive value of MIS on embryo morphology and IVF outcome. To do so, we measured MIS at the time of HCG administration 36 h prior to oocyte retrieval.

Methods: A total of 257 patients undergoing IVF were prospectively recruited. We measured MIS levels by enzyme-linked immunosorbent assay at the time of HCG, and compared the MIS values to day 3 FSH levels in the prediction of embryo morphology and IVF outcome.

Results: The distribution of MIS levels was skewed, with a median of 2.7 ng/ml (range 0 to 28.5 ng/ml). MIS values at the time of HCG administration inversely correlated with basal FSH levels (P = 0.002), and both correlated significantly with patient age, number of mature follicles, number of oocytes retrieved and serum estradiol levels. MIS levels correlated significantly with a greater number of 6-cell embryos and better embryo morphology score, while basal FSH levels did not correlate with these outcome variables. MIS levels > or =2.7 ng/ml portended improved oocyte quality as reflected in a higher implantation rate (P = 0.001) and a trend toward a better clinical pregnancy rate (P = 0.084).

Conclusions: MIS levels seem to predict not only ovarian reserve, but also embryo morphology. Measurement of MIS at the time of HCG administration may, therefore, in the future improve management of patients undergoing treatments with assisted reproductive technology.

MeSH terms

  • Anti-Mullerian Hormone
  • Chorionic Gonadotropin / administration & dosage*
  • Embryo, Mammalian / cytology*
  • Female
  • Fertilization in Vitro*
  • Glycoproteins / analysis*
  • Humans
  • Ovary / chemistry*
  • Prognosis
  • Testicular Hormones / analysis*
  • Treatment Outcome

Substances

  • Chorionic Gonadotropin
  • Glycoproteins
  • Testicular Hormones
  • Anti-Mullerian Hormone